Page last updated: 2024-09-05

lapatinib and pyrroles

lapatinib has been researched along with pyrroles in 42 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (pyrroles)	Trials (pyrroles)	Recent Studies (post-2010) (pyrroles)
1,919	305	1,442	26,129	2,815	12,100

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (38.10)	29.6817
2010's	25 (59.52)	24.3611
2020's	1 (2.38)	2.80

Authors

Authors	Studies
Bonomi, P	1
Berlin, JD; Lockhart, AC; Lockhart, C	1
Rabindran, SK	1
Saito, Y; Suzuki, Y; Tokuda, Y	1
Hampton, T	1
Bankhead, C	1
Berger, M; Lipton, A; Planas-Silva, MD; Viallet, J; Witkoski, A; Witters, LM	1
Force, T; Krause, DS; Van Etten, RA	1
Giordano, S; Petrelli, A	1
Nahleh, ZA	1
Guo, Z; Zhao, H	1
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B	1
Argyriou, AA; Dimitrakopoulos, F; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Koutras, AK	1
Gelderblom, H; Guchelaar, HJ; van Erp, NP	1
Dent, P; Grant, S; Martin, AP; Mitchell, C; Nephew, KP; Rahmani, M	1
Amaravadi, R	1
Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N	1
Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C	1
Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A	1
Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V	1
Addeo, R; Caraglia, M	1
Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E	1
Cortes, J; Roché, H	1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J	1
Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Tang, Y	1
Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A	1
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, H; Tang, Y	1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A	1
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S	1
Behera, R; Mensa-Wilmot, K; Thomas, SM	1
Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF	1
Croft, SL; Sanderson, L; Yardley, V	1
Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W	1
Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L	1
Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF	1
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT	1
Jiang, M; Liu, TT; Shen, GF; Shi, JH; Wang, Q	1
Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI	1
Diao, Y; Gao, N; Jiang, W; Jin, G; Jin, Z; Li, W; Liu, Y; Wang, X; Wang, Z; Zhong, J	1
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU	1
Chen, Y; Hin Cho, C; Imani, S; Jabbarzadeh Kaboli, P; Jomhori, M; Li, M; Luo, S; Shen, J; Wu, X; Wu, Z; Xiang, S; Xiao, Z; Zhao, Y	1

Reviews

12 review(s) available for lapatinib and pyrroles

Article	Year
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 1 Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome	2003
The epidermal growth factor receptor as a target for colorectal cancer therapy. Seminars in oncology, 2005, Volume: 32, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction	2005
Antitumor activity of HER-2 inhibitors. Cancer letters, 2005, Sep-08, Volume: 227, Issue:1 Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2	2005
[Molecular-targeted agents in breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab	2006
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature reviews. Cancer, 2007, Volume: 7, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab	2007
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Current medicinal chemistry, 2008, Volume: 15, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab	2008
Molecularly targeted therapy in breast cancer: the new generation. Recent patents on anti-cancer drug discovery, 2008, Volume: 3, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Estrogen; Sunitinib	2008
Medicinal chemistry strategies in follow-on drug discovery. Drug discovery today, 2009, Volume: 14, Issue:9-10 Topics: Animals; Atorvastatin; Bendamustine Hydrochloride; Benzazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Delivery Systems; Drug Discovery; gamma-Aminobutyric Acid; Heptanoic Acids; Humans; Lapatinib; Nitrogen Mustard Compounds; Pregabalin; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides	2009
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution	2009
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab	2011
Docetaxel combined with targeted therapies in metastatic breast cancer. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab	2012
Update on cardiotoxicity of anti-cancer treatments. European journal of clinical investigation, 2016, Volume: 46, Issue:3 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids	2016

Trials

1 trial(s) available for lapatinib and pyrroles

Article	Year
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9 Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult	2015

Article

Year

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9

Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult

2015

Other Studies

29 other study(ies) available for lapatinib and pyrroles

Article	Year
Trials probe new agents for kidney cancer. JAMA, 2006, Jul-12, Volume: 296, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib	2006
Three new drugs available to fight kidney cancer. Journal of the National Cancer Institute, 2006, Sep-06, Volume: 98, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A	2006
New hope for RCC patients. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib	2006
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncology reports, 2007, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2	2007
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2009
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Investigational new drugs, 2010, Volume: 28, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Humans; Indoles; Lapatinib; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Quinazolines; Sunitinib	2010
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer biology & therapy, 2009, Volume: 8, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Cell Death; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Indoles; Lapatinib; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines	2009
Autophagy can contribute to cell death when combining targeted therapy. Cancer biology & therapy, 2009, Volume: 8, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Death; Colonic Neoplasms; HCT116 Cells; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines	2009
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:8 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome	2010
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer biology & therapy, 2010, Nov-01, Volume: 10, Issue:9 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine	2010
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. Anticancer research, 2010, Volume: 30, Issue:12 Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1	2010
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert review of anticancer therapy, 2011, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib	2011
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular cancer therapeutics, 2011, Volume: 10, Issue:4 Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult	2011
[Renal tolerance of targeted therapies]. Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3 Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib	2012
Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular pharmacology, 2012, Volume: 81, Issue:4 Topics: Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; Genes, erbB-2; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines	2012
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular pharmacology, 2012, Volume: 81, Issue:5 Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4	2012
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Molecular pharmacology, 2012, Volume: 82, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Stress; Female; HSP70 Heat-Shock Proteins; Humans; Indoles; Lapatinib; Membrane Proteins; Mice; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; p38 Mitogen-Activated Protein Kinases; Pyrroles; Quinazolines; Reactive Oxygen Species	2012
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926 Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2013
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer biology & therapy, 2013, Oct-01, Volume: 14, Issue:10 Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays	2013
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4 Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African	2014
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult	2014
Activity of anti-cancer protein kinase inhibitors against Leishmania spp. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:7 Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome	2014
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. British journal of pharmacology, 2014, Volume: 171, Issue:24 Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles	2014
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7 Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib	2015
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. Journal of translational medicine, 2015, Jun-13, Volume: 13 Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays	2015
Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). Journal of photochemistry and photobiology. B, Biology, 2015, Volume: 153 Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Fluorescence Resonance Energy Transfer; Gefitinib; Indoles; Lapatinib; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrroles; Quinazolines; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sunitinib; Thermodynamics	2015
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific reports, 2016, 12-21, Volume: 6 Topics: Adenine; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line; Dendritic Cells; Female; Immunotherapy; Indoles; Lapatinib; Lymphocytes; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Spleen; Succinates; Sunitinib; Toll-Like Receptor 7	2016
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC cancer, 2017, Nov-03, Volume: 17, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms	2017
Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress. Gene, 2022, Mar-30, Volume: 816 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Berberine; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 6; DNA (Cytosine-5-)-Methyltransferase 1; Epigenesis, Genetic; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Signal Transduction; Transcriptome; Triple Negative Breast Neoplasms; Up-Regulation	2022